At a glance
ClinicalIndex Comparison Record- ✓Histologic or cytologic evidence of NSCLC with unresectable Stage IIIA (N2) or Stage IIIB disease
- ✓N2 disease documented by biopsy, FDG-PET, or CT (nodes >2 cm)
- ✓Stage IIIB requires N3 or T4 status, with N3 documented by biopsy, FDG-PET, or CT (nodes >2 cm)
- ✓Measurable or evaluable disease on CT, MRI, X-ray, or physical exam within 28 days prior to treatment
- ✕Prior chemotherapy or radiotherapy for lung cancer
- ✕Unintended weight loss >5% body weight in preceding 3 months
- ✕Symptomatic peripheral neuropathy or neuropathy ≥Grade 2
- ✕Prior malignancy except adequately treated skin cancer, in situ cervical cancer, or disease-free >5 years
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24
In Brief
A Phase 3 clinical trial evaluating Cisplatin, Etoposide, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 243 participants across 15 sites.
Detailed Summary
In a previous phase II study, patients with pathological stage IIIb (without pleural effusion) NSCLC were treated with concurrent cisplatin and etoposide plus thoracic radiotherapy followed by 3 cycles of consolidation therapy with docetaxel. Docetaxel was selected based upon a survival benefit in patients with recurrent NSCLC. This trial will evaluate the role of consolidation therapy with docetaxel in patients with unresectable stage III disease. The purpose of the trial is to evaluate survival and toxicities of the regimens employed.
Study Details
Timeline
Interventions
Cisplatin 50 mg/m2 day 1, 8, 29, 36
Etoposide 50 mg/m2, days 1-5, 29-33
Radiation 5940 cGy (180 cGy/day)
docetaxel 75mg/m2 q3wk x 3 cycles